Biological Safety Testing Products and Services Market: Competitive Strategies and Key Players

Biological Safety Testing Products and Services Market

The global Biological Safety Testing Products and Services Market size was valued at USD 5.26 billion in 2025 and is projected to grow from USD 5.82 billion in 2026 to USD 13.11 billion by 2034, registering a CAGR of 10.68% during the forecast period (2026–2034). Increasing demand for biologics, vaccines, cell and gene therapies, and other advanced pharmaceutical products supports this growth. Pharmaceutical and biotechnology companies increasingly rely on biological safety testing to identify contaminants, verify product quality, and meet regulatory requirements. As biopharmaceutical manufacturing expands, the need for reliable testing products, specialized laboratory services, and advanced analytical methods continues to increase.

Biological safety testing helps manufacturers evaluate the safety of biological products throughout development and production. These tests detect microbial contamination, adventitious agents, endotoxins, and other potential hazards that can affect product quality and patient safety. Growing investments in biopharmaceutical research, the expansion of contract testing laboratories, and advances in molecular testing technologies are creating additional opportunities for industry participants.

For detailed market insights, growth forecasts, and competitive analysis, visit: https://straitsresearch.com/report/biological-safety-testing-products-and-services-market

Market Drivers

Growing Demand for Biopharmaceuticals and Advanced Therapies

The rising demand for monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies is a major factor supporting market growth. These products involve complex biological manufacturing processes that require strict contamination control and safety verification. Manufacturers use biological safety testing at different production stages to identify potential risks and maintain consistent product quality.

The expansion of biologics pipelines also increases the need for specialized testing capabilities. Cell and gene therapies, in particular, require rigorous testing because their manufacturing processes involve living cells, viral vectors, and other sensitive biological materials. This creates demand for testing methods that can detect contaminants accurately while supporting product development and commercialization.

Stringent Regulatory Requirements for Product Safety

Regulatory authorities require pharmaceutical and biotechnology manufacturers to demonstrate the safety, identity, purity, and quality of biological products. Testing for sterility, endotoxins, mycoplasma, and viral contaminants helps manufacturers meet applicable quality standards and reduce the risk of unsafe products reaching patients.

Compliance requirements encourage companies to invest in validated testing procedures, qualified laboratory infrastructure, and specialized analytical services. The need for reliable documentation and consistent testing results also supports demand for external testing providers with established quality systems and technical expertise.

Technological Advancements in Testing Methods

Advances in molecular biology, nucleic acid amplification, and automated laboratory systems are improving the speed and sensitivity of biological safety testing. These technologies help laboratories detect contaminants and analyze complex biological samples more efficiently. Automation can also reduce manual handling, improve workflow consistency, and support higher testing volumes.

As pharmaceutical manufacturers seek faster development timelines and more efficient quality-control processes, demand for advanced testing platforms and specialized laboratory services is expected to increase.

Market Challenges

High Testing Costs and Complex Validation Requirements

Biological safety testing often requires specialized equipment, trained personnel, controlled laboratory environments, and validated analytical procedures. These requirements increase operating expenses, particularly for smaller biotechnology companies and laboratories with limited resources. Complex products may also require multiple testing methods, increasing the time and cost associated with quality assessment.

Long Testing Timelines and Technical Limitations

Certain traditional testing methods require extended incubation periods or multiple analytical steps before results become available. Delays can affect manufacturing schedules, product release, and clinical development timelines. Although newer molecular and rapid-testing techniques can improve efficiency, laboratories must establish their suitability and demonstrate reliable performance before replacing established methods. Differences in sample characteristics and assay requirements can further complicate testing workflows.

Market Segmentation

The Biological Safety Testing Products and Services Market can be analyzed by product and service, test type, application, end user, and region.

By Product and Service

The market includes biological safety testing products and biological safety testing services. Products cover testing kits, reagents, consumables, and related laboratory materials used to assess biological safety. Demand for these products is supported by recurring testing requirements across pharmaceutical development and manufacturing.

Services include specialized laboratory testing, analytical assessments, and outsourced safety evaluations. Service providers help pharmaceutical and biotechnology companies access technical expertise and testing infrastructure without maintaining every capability internally. The expansion of complex biologics pipelines supports demand for external testing services.

By Test Type

Key test types include sterility testing, endotoxin testing, mycoplasma testing, bioburden testing, and adventitious agent detection. Sterility testing helps determine whether products are free from viable contaminating microorganisms, while endotoxin testing identifies bacterial endotoxins that may pose risks to patients.

Mycoplasma testing is particularly important for products manufactured using cell cultures. Bioburden testing measures microbial contamination before sterilization, where applicable, and adventitious agent testing helps identify unintended biological contaminants. The need for comprehensive quality control across biological manufacturing supports demand for these testing categories.

By Application

Applications include vaccines and therapeutics, blood and blood products, gene therapy products, cellular therapies, and other biological products. Vaccines and therapeutics require extensive safety assessments to support consistent manufacturing quality. The growing development of cell and gene therapies creates additional demand for specialized testing because these products involve complex materials and manufacturing processes.

By End User

Pharmaceutical and biotechnology companies represent a major end-user group because they conduct safety assessments during research, development, clinical production, and commercial manufacturing. Contract research organizations, contract development and manufacturing organizations, and specialized testing laboratories also contribute to demand. Outsourcing allows companies to access validated testing capabilities, manage laboratory costs, and scale operations according to project requirements.

Regional Insights

North America

North America is supported by an established pharmaceutical and biotechnology industry, substantial research investment, and a well-developed regulatory framework. The presence of biologics developers, advanced therapy manufacturers, and specialized testing laboratories supports demand for biological safety testing products and services. Continued investment in innovative therapies and quality-control infrastructure strengthens regional growth prospects.

Europe

Europe benefits from established pharmaceutical manufacturing capabilities, biotechnology research, and stringent product-quality requirements. Pharmaceutical companies and testing laboratories invest in reliable analytical methods to support the development and production of biological medicines. Collaboration between research institutions, biotechnology companies, and contract testing providers also supports market development.

Asia-Pacific

Asia-Pacific offers growth opportunities through expanding pharmaceutical manufacturing, increasing biotechnology investment, and rising demand for vaccines and biologics. Countries such as China, India, Japan, and South Korea contribute to regional research and production capabilities. The expansion of contract manufacturing and testing infrastructure is encouraging pharmaceutical companies to strengthen their biological safety testing capacity.

Latin America, Middle East & Africa

Latin America, the Middle East, and Africa are developing markets for biological safety testing products and services. Pharmaceutical manufacturing investment, improved laboratory infrastructure, and growing attention to medicine quality support demand. Market expansion depends on access to advanced testing technologies, skilled professionals, regulatory capabilities, and investment in specialized laboratory facilities.

Key Players Analysis

The competitive landscape includes established life sciences companies, specialized testing laboratories, and providers of analytical instruments, reagents, and laboratory services. Companies compete through testing accuracy, regulatory compliance, service reliability, technological capabilities, turnaround times, and geographic reach. Investments in molecular testing, laboratory automation, and expanded service portfolios help providers address the changing requirements of pharmaceutical and biotechnology customers.

Key players in the Biological Safety Testing Products and Services Market include:

• Charles River Laboratories International, Inc.

• Thermo Fisher Scientific Inc.

• Merck KGaA

• Lonza Group AG

• Eurofins Scientific SE

• SGS SA

• WuXi AppTec

• Sartorius AG

• Nelson Laboratories, LLC

• Avance Biosciences

These companies participate in different areas of the testing ecosystem, including specialized laboratory services, analytical products, quality-control solutions, and support for biopharmaceutical development. Competitive positioning depends on the ability to deliver dependable results, maintain appropriate quality systems, and support increasingly complex biological products.

Conclusion

The Biological Safety Testing Products and Services Market is positioned for substantial growth as demand for biologics, vaccines, and advanced therapies increases worldwide. The market is projected to rise from USD 5.82 billion in 2026 to USD 13.11 billion by 2034, at a CAGR of 10.68% during the forecast period. Regulatory requirements, advances in testing technologies, and the expansion of biopharmaceutical manufacturing are important growth factors. Although high testing costs, validation requirements, and lengthy procedures present challenges, innovation and outsourcing opportunities are expected to support market development.

About Us

Straits Research is a leading market research and intelligence organization specializing in research, analytics, and advisory services. The company provides comprehensive market reports, industry insights, and strategic business intelligence across multiple industries, helping organizations identify growth opportunities and make informed business decisions.

Contact Us

Email: [email protected]

Tel: +1 646 905 0080 (U.S.)

Tel: +44 203 695 0070 (U.K.)